A
$112.75
Agilent Technologies, Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and App...
Recent News
Emerald Growth Equity Strategy Sold Agilent (A) Due to Compression in the Margin of Safety
Emerald Wealth Partners, an independent asset and wealth management firm based in Zurich, released its Q4 2025 investor letter for the “Growth Equity Strategy.” A copy of the letter is available to download here. In 2025, the strategy returned +3.1% (gross) and +3.0% (net), resulting in the year-to-date return of 16.7% (gross) and +16.0% (net). […]
2 Large-Cap Stocks to Research Further and 1 We Brush Off
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.
Citi Flags Agilent Technologies, Cuts Icon PLC Target, and More
Citi swept through its life science tools and diagnostics coverage on Wednesday, opening a 90-day upside catalyst watch on Agilent Technologies (NYSE:A) while trimming its price target on Icon PLC (NASDAQ:ICLR) following a turbulent earnings season for the sector. Alongside those moves, the firm named Agilent its top tools pick, Natera (NASDAQ:NTRA) its top diagnostics ... Citi Flags Agilent Technologies, Cuts Icon PLC Target, and More
If You Invested $1000 in Keysight a Decade Ago, This is How Much It'd Be Worth Now
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Jim Cramer on Agilent Technologies: “I Don’t Think You Need It”
Agilent Technologies, Inc. (NYSE:A) is one of the stocks on which Jim Cramer expressed his thoughts. A caller asked if the stock will ever come back, and here’s what Cramer had to say in response: You know, they do so much test and measurement that is biotech. It’s almost like a Danaher, which stopped working. […]